CRISPR Therapeutics (CRSP) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 540.1% versus a loss of 25.9%. Over five years, KOD leads with a -18.7% price change compared with -46.0% for CRSP. Kodiak Sciences is the larger company by market cap ($5.92 billion vs $4.88 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | KOD |
|---|---|---|
| Share price | $50.44 | $94.26 |
| Market cap | $4.88B | $5.92B |
| 1-day change | -3.65% | +3.49% |
| YTD return | -0.17% | +225.75% |
| 1-year return | -25.87% | +540.06% |
| 5-year return | -46.03% | -18.66% |
| EPS (TTM) | $-4.74 | $-4.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | — |
| Revenue growth (YoY) | -90.59% | — |
| Net income (latest FY) | $-581.60M | $-229.97M |
| Operating margin | -18933.65% | — |
| Net margin | -16569.77% | — |
| 52-week high | $78.38 | $104.00 |
| 52-week low | $44.12 | $10.94 |
| Distance from 52-week high | -35.65% | -9.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +73.59% | +23.77% |
| Average volume | 1.59M | 1.56M |
| Shares outstanding | 96.69M | 62.85M |
| Employees | — | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed CRSP by 565.9 percentage points over the past year.
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
CRSP vs KOD FAQ
Which is bigger, CRISPR Therapeutics or Kodiak Sciences?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.92B compared with $4.88B for CRISPR Therapeutics (CRSP).
Which stock has performed better over the past year, CRSP or KOD?
KOD returned +540.06% over the past 12 months, compared with -25.87% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Kodiak Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.